CAS: 1384426-12-3

NT157, a small tyrphostin, inhibits IRS, IGF-1R, and STAT3 in TME, reducing cancer cell survival.

NT157

NT-157 is a small-molecule drug that targets the JAK2 V617F mutation found in chronic myeloid leukemia cells. It is being investigated for its potential use as a therapy to treat cancer. NT-157 inhibits the activity of JAK2, which is an enzyme responsible for transmitting signals from outside of the cell (the extracellular environment) to inside the cell. NT-157 has been shown to be effective against cancer cells and has induced tumor regression in mice models with leukemia. The cellular targets of NT-157 are currently unknown, but it may act by disrupting microenvironmental signaling pathways or inhibiting energy metabolism in cancer cells. NT-157 has also been shown to bind to DNA and activate transcriptional response elements that are involved in cell signaling pathways.